Dependence on PI3K and RAS-RAF pathways drives the activity of the combination of everolimus (RAD001) and RAF265, a novel inhibitor of the RAF-MAPK pathway, invitro and in vivo

被引：0
|
作者：
Mordant, Pierre [1 ]
Loriot, Yohann [1 ]
Leteur, Celine [1 ]
Tao, Yungan [1 ]
Bourhis, Jean [1 ]
Soria, Jean-Charles [1 ]
Deutsch, Eric [1 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
429
引用
收藏
页数：1
相关论文
共 33 条
  • [1] Dependence on PI3K and RAS-RAF pathways drives the activity of the combination of RAD001 and RAF265, a novel inhibitor of the RAF-MAPK pathway
    Mordant, P.
    Leteur, C.
    Bourhis, J.
    Soria, J. C.
    Deutsch, E.
    EJC SUPPLEMENTS, 2008, 6 (12): : 103 - 103
  • [2] Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination
    Mordant, Pierre
    Loriot, Yohann
    Leteur, Celine
    Calderaro, Julien
    Bourhis, Jean
    Wislez, Marie
    Soria, Jean-Charles
    Deutsch, Eric
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (02) : 358 - 368
  • [3] The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways
    Susi Barollo
    Loris Bertazza
    Enke Baldini
    Salvatore Ulisse
    Elisabetta Cavedon
    Marco Boscaro
    Raffaele Pezzani
    Caterina Mian
    Investigational New Drugs, 2014, 32 : 626 - 635
  • [4] The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways
    Barollo, Susi
    Bertazza, Loris
    Baldini, Enke
    Ulisse, Salvatore
    Cavedon, Elisabetta
    Boscaro, Marco
    Pezzani, Raffaele
    Mian, Caterina
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (04) : 626 - 635
  • [5] PI-103 and Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo by Blocking Ras/Raf/MAPK and PI3K/AKT/mTOR Pathways
    Gedaly, Roberto
    Angulo, Paul
    Hundley, Jonathan
    Daily, Michael F.
    Chen, Changguo
    Koch, Alvaro
    Evers, B. Mark
    LIVER TRANSPLANTATION, 2011, 17 (06) : S87 - S87
  • [6] Intra-Cellular Calcium Signaling Pathways (PKC, RAS/RAF/MAPK, PI3K) in Lamina Cribrosa Cells in Glaucoma
    Irnaten, Mustapha
    Duff, Aisling
    Clark, Abbot
    O'Brien, Colm
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (01) : 1 - 14
  • [7] Discovery and characterization of a highly selective inhibitor of B-RAF, PI3K, and mTOR kinases with antitumor activity in BRAF and B-RAF/PI3K pathway double mutant xenograft models
    Reddy, Sanjeeva P.
    Jaleel, Mahaboobi
    Nyavanandi, Vijay K.
    Ramachandra, Murali
    Subramanya, Hosahalli
    Basavaraju, Aravind
    Sihorkar, Vaibhav
    Smith, Roger A.
    Gupta, Sandeep
    Thompson, Scott K.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [8] PI-103 and Sorafenib Inhibit Hepatocellular Carcinoma Cell Proliferation by Blocking Ras/Raf/MAPK and PI3K/AKT/mTOR Pathways
    Gedaly, Roberto
    Angulo, Paul
    Hundley, Jonathan
    Daily, Michael F.
    Chen, Changguo
    Koch, Alvaro
    Evers, B. Mark
    ANTICANCER RESEARCH, 2010, 30 (12) : 4951 - 4958
  • [9] In vivo antitumor activity of NVP-BEZ235, a dual PI3K/mTOR inhibitor, and RAD001 (everolimus), an mTOR inhibitor, in endometrial cancer
    Shoji, Keiko
    Oda, Katsutoshi
    Nakagawa, Shunsuke
    Ikeda, Yuji
    Kashiyama, Tomoko
    Miyamoto, Yuichiro
    Tanikawa, Michihiro
    Kuramoto, Hiroyuki
    Hiraike-Wada, Osamu
    Yano, Tetsu
    Taketani, Yuji
    CANCER RESEARCH, 2011, 71
  • [10] Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor
    Menges, C. W.
    McCance, D. J.
    ONCOGENE, 2008, 27 (20) : 2934 - 2940
1234